Comparative efficacy and safety of clarithromycin in the treatment of bacterial sinusitis
https://doi.org/10.21518/2079-701X-2014-15-18-23
Abstract
Inflammatory pathology of the nasal cavity and paranasal sinuses is one of the major challenges in otorhinolaryngology today. Among patients hospitalized in ENT units, the incidence of inflammatory diseases of the paranasal sinuses is up to 36%. Modern macrolides (especially clarithromycin and azithromycin) are among the most common antibiotics in outpatient practice. The revival of interest in macrolide antibiotics was conditioned by an increase in their clinical value in infectious pathology of intracellular pathogens where macrolides showed a unique activity.
About the Authors
V. I. Popadyuk
People's Friendship University of Russia
Russian Federation
Russian Federation
A. I. Chernolev
People's Friendship University of Russia
Russian Federation
Russian Federation
I. A. Korshunova
People's Friendship University of Russia
Russian Federation
Russian Federation
References
1. Пальчун В.Т., Крюков А.И. Оториноларингология: Руководство для врачей. М.: Медицина, 2001: 616.
2. Bryskier A, Butzler J-P. Macrolides. In: RG.Finch, D.Greenwood, S.R.Norrby, RJ.Whitley, editors. Antibiotic and Chemotherapy. Anti-infective agents and their use in therapy. Churchill Livingstone, 8th edition. 2003: 310-25.
3. Chey WD, Wong BCY. American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection. Am J Gastroenterol, 2007, 102: 1808-25.
4. Neu HC. The development of macrolides: clarithromycin in perspective. J. Antimicrob Chemother, 1991, 27 (Suppl A): 1-9.
5. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J. Antimicrob Chemother, 1993, 31 (Suppl C): 1-9.
6. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002, 34: 482-92.
7. Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phe-notypes. Clin Infect Dis 2004, 38 (Suppl. 4): 322-7.
8. Kozlov RS, Bogdanovitch TM, Appelbaum PC et al. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia. Antimicrob Agents Chemother 2002, 46: 2963-8.
9. Дюфалак (лактулоза). Научная монография. М., 2001.
10. Практические рекомендации Всемирной Гастроэнтерологической организации (WGO). Пробиотики и пребиотики, май, 2008.
11. Grewe JWM, Gouma DJ, Buurman WA: Complications in obstructive jaundice: Role of endotoxins. Scand J Gastroenterol 1992, 27(Suppl 194): 8-12.
12. van Leeuwen PAM, Hong RW, Rounds JD, Wilmore DW, Wesdorp RIC: Hepatic failure and coma following liver resection is reversed by manipulation of gut contents: the role of endotoxin. Surgery 1991, 110: 169-75.
13. Huchzermeyer H, Schumann C: Lactulose - a multifaceted substance. Z Gastroenterol 1997, 35: 945-55.
14. Kudoh K, Shimizu J, Wada M et al.: Effect of indigestable saccharides on B lymphocyte response of intestinal mucosa and cecal fermentation in rats. J Nutr Sci Vitaminol 1998, 44: 103-12.
15. Pain JA, Cahill CJ, Gilbert JM, Johnson CD, Trapnell JE, Bailey ME: Prevention of postoperative renal dysfunction in patients with obstructive jaundice: a multicentre study of bile salts and lactulose. Br J Surg 1991, 78: 467-9.
16. Madsen KL, Doyle JS, Jewell LD, Tavernini MM & Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 1999. 116, 1107-1114.
17. Fleige1 S, Preisinger W, Meyer1 HHD, Pfaffl1 MW. Lactulose: effect on apoptotic- and immunological-markers in the gastro-intestinal tract of pre-rumi-nant calves. VeterinarniMedicina. 52, 2007 (10): 437-444.
18. Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World Journal of Gastroenterology. 2006. 12, 5941-5950.
19. Bruzzese E, Volpicelli M, Squeglia V, et al. A formula containing galacto- and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. Clin Nutr. 2009. 28, 156-161.
20. Arslanoglu S, Moro GE & Boehm G. Early supplementation of prebiotic oligosaccharides protects formula-fed infants against infections during the first 6 months of life.J. Nutr, 2007, 137: 2420-2424.
21. Лопатин А., Гамов В. Острый синусит: Этиология, патогенез, диагностика и принципы лечения. Учебное пособие. ISBN: 978-5-9986-0162-0. Издательство: Медицинское информационное агентство, 2014.
22. Evangelos J. Giamarellos-Bourboulis, Theodoros Adamis et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMCInfectious Diseases, 2006, 6: 31-39.
Review
For citations:
Popadyuk VI, Chernolev AI, Korshunova IA. Comparative efficacy and safety of clarithromycin in the treatment of bacterial sinusitis. Meditsinskiy sovet = Medical Council. 2014;(15):18-23. (In Russ.) https://doi.org/10.21518/2079-701X-2014-15-18-23
Views:
401
Email this article 